A Comparison between Heparin and Low-Dose Aspirin as Adjunctive Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction

New England Journal of Medicine

Volumn 323, Issue 21, 1990, Pages 1433-1437

  Hsia, Judith ^a   Hamilton, William P ^c   Kleiman, Neal ^b   Roberts, Robert ^b   Chaitman, Bernard R ^c   Ross, Allan M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ASPIRIN; COMPARATIVE STUDY; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HUMAN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0025092298     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199011223232101     Document Type: Article

References (21)

1. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317: 1613–8.
2. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo—Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525–30.
3. Van de Werf F. Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. J Am Coll Cardiol 1988; 12: 14A–19A.
4. Topol EJ, George BS, Kereiakes DJ, et al. A multicenter, randomized, controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–6.
5. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988; 85: 353–9.
6. Rao AK, Pratt C, Berke A, TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial — Phase I: hemorrhagic manifestations and changes in plasma ftbrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11.
7. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932–6.
8. Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583–7.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
10. Kander NH, Holland KJ, Pitt B, Topol EJ. A randomized pilot trial of brief versus prolonged heparin after successful reperfusion in acute myocardial infarction. Am J Cardiol 1990; 65: 139–42.
11. Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989; 13: 1469–76.
12. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–27.
13. Bleich SD, Nichols T, Schumacher R, et al. The role of heparin following coronary thrombolysis with tissue plasminogen activator (t-PA). Circulation 1989; 80: Suppl II: II-113. abstract.
14. Bates ER, Califf RM, Stack RS, et al. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) Trial: influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989; 13: 12–8.
15. National Heart Foundation of Australia Coronary Thrombolysis Group. A randomized comparison of oral aspirin/dipyridamole versus intravenous heparin after rTPA for acute myocardial infarction. Circulation 1989; 80: Suppl II: II-14. abstract.
16. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72.
17. 2 production in healthy subjects. Thromb Res 1980; 17: 317–27.
18. Simoons ML, van den Brand M, de Zwaan C, et al. Improved survival after early thrombolysis in acute myocardial infarction: a randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985; 2: 578–81.
19. Mathey DG, Schofer J, Sheehan FH, et al. Improved survival up to four years after early coronary thrombolysis. Am J Cardiol 1988; 61: 524–9.
20. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71.
21. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–5.